NewcelX Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
4
- Stock Symbol
-
NCEL
- Investments
-
1
- Share Price
-
$2.58
- (As of Friday Closing)
NewcelX General Information
Description
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
Contact Information
Website
www.newcelx.comCorporate Office
- Hohstrasse 1
- 8302 Kloten
- Switzerland
Corporate Office
- Hohstrasse 1
- 8302 Kloten
- Switzerland
NewcelX Stock Performance
As of 13-Nov-2026, NewcelX’s stock price is $2.58. Its current market cap is $15.1M with 5.78M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.58 | $2.69 | $1.83 - $5.12 | $15.1M | 5.78M | 14.1K | $0.56 |
NewcelX Financials Summary
As of 30-Jun-2026, NewcelX has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 17,863 | 10,902 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (4,158) | (2,606) | (1,746) | (2,509) |
| Net Income | 55 | (8,300) | (7,197) | (3,332) |
| Total Assets | 9,700 | 11,445 | 903 | 2,204 |
| Total Debt | 392 | 355 | 2,665 | 2,623 |
NewcelX Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NewcelX Comparisons
Industry
Financing
Details
NewcelX Competitors (49)
One of NewcelX’s 49 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Alector | Formerly VC-backed | South San Francisco, CA |
NewcelX Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NewcelX Patents
NewcelX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220387514-A1 | Methods of treating acute respiratory distress syndrome | Inactive | 02-Jun-2021 | ||
| EP-3384286-A1 | Methods for differentiating and purifying pancreatic endocrine cells | Active | 30-Nov-2015 | ||
| EP-3384286-A4 | Methods for differentiating and purifying pancreatic endocrine cells | Active | 30-Nov-2015 | ||
| EP-3384286-B1 | Methods for differentiating and purifying pancreatic endocrine cells | Active | 30-Nov-2015 | ||
| EP-4231015-A1 | Methods for differentiating and purifying pancreatic endocrine cells | Active | 30-Nov-2015 | A61K35/39 |
NewcelX Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NewcelX Acquisitions (1)
NewcelX’s most recent deal was a Merger/Acquisition with NewcelX (Drug Discovery). The deal was made on 30-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NewcelX (Drug Discovery) | 30-Oct-2025 | Merger/Acquisition | Drug Discovery |
NewcelX ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
NewcelX Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| NewcelX (Mazindol Asset Portfolio) | Kloten, Switzerland |
NewcelX FAQs
-
When was NewcelX founded?
NewcelX was founded in 2009.
-
Where is NewcelX headquartered?
NewcelX is headquartered in Kloten, Switzerland.
-
What is the size of NewcelX?
NewcelX has 4 total employees.
-
What industry is NewcelX in?
NewcelX’s primary industry is Drug Delivery.
-
Is NewcelX a private or public company?
NewcelX is a Public company.
-
What is NewcelX’s stock symbol?
The ticker symbol for NewcelX is NCEL.
-
What is the current stock price of NewcelX?
As of 13-Nov-2026 the stock price of NewcelX is $2.58.
-
What is the current market cap of NewcelX?
The current market capitalization of NewcelX is $15.1M.
-
Who are NewcelX’s competitors?
Regenxbio, Genetix Biotherapeutics, Capricor Therapeutics, Lisata Therapeutics, and Alector are some of the 49 competitors of NewcelX.
-
What is NewcelX’s annual earnings per share (EPS)?
NewcelX’s EPS for 12 months was $0.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
